Oppenheimer Asset Management Inc. Cuts Stock Position in Haleon plc (NYSE:HLN)

Oppenheimer Asset Management Inc. trimmed its holdings in Haleon plc (NYSE:HLN) by 3.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 739,344 shares of the company’s stock after selling 28,258 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Haleon were worth $7,053,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. FMR LLC lifted its stake in Haleon by 5.8% in the 3rd quarter. FMR LLC now owns 104,918,269 shares of the company’s stock worth $1,110,035,000 after purchasing an additional 5,768,117 shares in the last quarter. Wellington Management Group LLP lifted its stake in Haleon by 49.9% in the 3rd quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock worth $96,833,000 after purchasing an additional 3,046,841 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Haleon by 25.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock worth $53,791,000 after purchasing an additional 1,026,939 shares in the last quarter. Natixis Advisors LLC lifted its stake in Haleon by 142.5% in the 3rd quarter. Natixis Advisors LLC now owns 1,473,767 shares of the company’s stock worth $15,593,000 after purchasing an additional 866,070 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Haleon by 29.8% in the 4th quarter. Bank of New York Mellon Corp now owns 2,071,017 shares of the company’s stock worth $19,758,000 after purchasing an additional 475,934 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors.

Haleon Stock Performance

Shares of NYSE:HLN opened at $10.18 on Friday. The stock has a market capitalization of $46.06 billion, a P/E ratio of 29.93, a PEG ratio of 2.82 and a beta of 0.28. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The firm has a fifty day simple moving average of $9.59 and a two-hundred day simple moving average of $9.83. Haleon plc has a 52 week low of $7.89 and a 52 week high of $10.80.

Haleon (NYSE:HLN) last issued its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The company had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.38 billion. On average, analysts expect that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on HLN shares. Sanford C. Bernstein downgraded Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Morgan Stanley downgraded Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Three equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Haleon has an average rating of “Moderate Buy” and an average target price of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.